<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38881657</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-302X</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in microbiology</Title><ISOAbbreviation>Front Microbiol</ISOAbbreviation></Journal><ArticleTitle>Clinical and prognostic implications of hyaluronic acid in patients with COVID-19 reinfection and first infection.</ArticleTitle><Pagination><StartPage>1406581</StartPage><MedlinePgn>1406581</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1406581</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmicb.2024.1406581</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Previous research has shown that human identical sequences of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) promote coronavirus disease 2019 (COVID-19) progression by upregulating hyaluronic acid (HA). However, the association of HA with mortality and long COVID in SARS-CoV-2 reinfection and first infection is unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Patients with COVID-19 at Beijing Ditan Hospital from September 2023 to November 2023 were consecutively enrolled. SARS-CoV-2 reinfections were matched 1:2 with first infections using a nearest neighbor propensity score matching algorithm. We compared the hospital outcomes between patients with COVID-19 reinfection and first infection. The association between HA levels and mortality and long COVID in the matched cohort was analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The reinfection rate among COVID-19 hospitalized patients was 25.4% (62 cases). After propensity score matching, we found that reinfection was associated with a better clinical course and prognosis, including lower levels of C-reactive protein and erythrocyte sedimentation rate, fewer cases of bilateral lung infiltration and respiratory failure, and shorter viral clearance time and duration of symptoms (<i>p</i>&#x2009;&lt;&#x2009;0.05). HA levels were significantly higher in patients with primary infection [128.0 (90.5, 185.0) vs. 94.5 (62.0, 167.3), <i>p</i>&#x2009;=&#x2009;0.008], those with prolonged viral clearance time [90.5 (61.5, 130.8) vs. 130.0 (95.0, 188.0), <i>p</i>&#x2009;&lt;&#x2009;0.001], and deceased patients [105.5 (76.8, 164.5) vs. 188.0 (118.0, 208.0), <i>p</i>&#x2009;=&#x2009;0.002]. Further analysis showed that HA was an independent predictor of death (AUC: 0.789), and the risk of death increased by 4.435 times (OR&#x2009;=&#x2009;5.435, 95% CI&#x2009;=&#x2009;1.205-24.510, <i>p</i>&#x2009;=&#x2009;0.028) in patients with high HA levels. We found that patients with HA levels above 116&#x2009;ng/mL had an increased risk of death. However, the incidence of long COVID was similar in the different HA level groups (<i>p</i> &gt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Serum HA may serve as a novel biomarker for predicting COVID-19 mortality in patients with SARS-CoV-2 reinfection and first infection. However, HA levels may not be associated with long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Li, Han and Li.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Yanyan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Han</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Institute of Infectious Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Microbiol</MedlineTA><NlmUniqueID>101548977</NlmUniqueID><ISSNLinking>1664-302X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">first infection</Keyword><Keyword MajorTopicYN="N">hyaluronic acid</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">reinfection</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus-2</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>17</Day><Hour>5</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38881657</ArticleId><ArticleId IdType="pmc">PMC11178136</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2024.1406581</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allegra L., Della Patrona S., Petrigni G. (2012). Hyaluronic acid: perspectives in lung diseases. Handb. Exp. Pharmacol. 207, 385&#x2013;401. doi: 10.1007/978-3-642-23056-1_17</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-23056-1_17</ArticleId><ArticleId IdType="pubmed">22566234</ArticleId></ArticleIdList></Reference><Reference><Citation>Ao D., He X., Liu J., Xu L. (2023). Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period. Signal Transduct. Target. Ther. 8:466. doi: 10.1038/s41392-023-01724-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01724-w</ArticleId><ArticleId IdType="pmc">PMC10739883</ArticleId><ArticleId IdType="pubmed">38129394</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes H. W., Demirdjian S., Haddock N. L., Kaber G., Martinez H. A., Nagy N., et al. . (2023). Hyaluronan in the pathogenesis of acute and post-acute COVID-19 infection. Matrix Biol. 116, 49&#x2013;66. doi: 10.1016/j.matbio.2023.02.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2023.02.001</ArticleId><ArticleId IdType="pmc">PMC9899355</ArticleId><ArticleId IdType="pubmed">36750167</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin D. A., Gulick R. M., Martinez F. J. (2020). Severe Covid-19. N. Engl. J. Med. 383, 2451&#x2013;2460. doi: 10.1056/NEJMcp2009575</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp2009575</ArticleId><ArticleId IdType="pubmed">32412710</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya M., Sharma A. R., Dhama K., Agoramoorthy G., Chakraborty C. (2022). Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the omicron period. Int. Immunopharmacol. 108:108766. doi: 10.1016/j.intimp.2022.108766, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.108766</ArticleId><ArticleId IdType="pmc">PMC8986476</ArticleId><ArticleId IdType="pubmed">35413676</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J. W., Maldonado D. R., Kowalski B. L., Miecznikowski K. B., Kyin C., Gornbein J. A., et al. . (2022). Best practice guidelines for propensity score methods in medical research: consideration on theory, implementation, and reporting. A Review. Arthroscopy 38, 632&#x2013;642. doi: 10.1016/j.arthro.2021.06.037, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2021.06.037</ArticleId><ArticleId IdType="pubmed">34547404</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen C., Pulliam J. (2023). COVID-19 infection, reinfection, and the transition to endemicity. Lancet 401, 798&#x2013;800. doi: 10.1016/S0140-6736(22)02634-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02634-4</ArticleId><ArticleId IdType="pmc">PMC9934854</ArticleId><ArticleId IdType="pubmed">36930672</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Forecasting Team (2023). Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet 401, 833&#x2013;842. doi: 10.1016/S0140-6736(22)02465-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02465-5</ArticleId><ArticleId IdType="pmc">PMC9998097</ArticleId><ArticleId IdType="pubmed">36930674</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangi T., Palacio N., Sanchez S., Park M., Class J., Visvabharathy L., et al. . (2021). Cross-protective immunity following coronavirus vaccination and coronavirus infection. J. Clin. Invest. 131:e151969. doi: 10.1172/JCI151969, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI151969</ArticleId><ArticleId IdType="pmc">PMC8670840</ArticleId><ArticleId IdType="pubmed">34623973</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhama K., Nainu F., Frediansyah A., Yatoo M. I., Mohapatra R. K., Chakraborty S., et al. . (2023). Global emerging omicron variant of SARS-CoV-2: impacts, challenges and strategies. J. Infect. Public Health 16, 4&#x2013;14. doi: 10.1016/j.jiph.2022.11.024, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.11.024</ArticleId><ArticleId IdType="pmc">PMC9675435</ArticleId><ArticleId IdType="pubmed">36446204</ArticleId></ArticleIdList></Reference><Reference><Citation>Eythorsson E., Runolfsdottir H. L., Ingvarsson R. F., Sigurdsson M. I., Palsson R. (2022). Rate of SARS-CoV-2 reinfection during an omicron wave in Iceland. JAMA Netw. Open 5:e2225320. doi: 10.1001/jamanetworkopen.2022.25320, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.25320</ArticleId><ArticleId IdType="pmc">PMC9350711</ArticleId><ArticleId IdType="pubmed">35921113</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Pe&#xf1;as C., Notarte K. I., Macasaet R., Velasco J. V., Catahay J. A., Ver A. T., et al. . (2024). Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: a systematic review and meta-analysis. J. Infect. 88, 77&#x2013;88. doi: 10.1016/j.jinf.2023.12.004, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.12.004</ArticleId><ArticleId IdType="pubmed">38101521</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira V. H., Solera J. T., Hu Q., Hall V. G., Arbol B. G., Rod Hardy W., et al. . (2022). Homotypic and heterotypic immune responses to omicron variant in immunocompromised patients in diverse clinical settings. Nat. Commun. 13:4489. doi: 10.1038/s41467-022-32235-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32235-x</ArticleId><ArticleId IdType="pmc">PMC9352686</ArticleId><ArticleId IdType="pubmed">35927279</ArticleId></ArticleIdList></Reference><Reference><Citation>Flacco M. E., Acuti Martellucci C., Baccolini V., De Vito C., Renzi E., Villari P., et al. . (2022). Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis. Eur. J. Clin. Investig. 52:e13845. doi: 10.1111/eci.13845, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13845</ArticleId><ArticleId IdType="pmc">PMC9353414</ArticleId><ArticleId IdType="pubmed">35904405</ArticleId></ArticleIdList></Reference><Reference><Citation>Garantziotis S. (2022). Modulation of hyaluronan signaling as a therapeutic target in human disease. Pharmacol. Ther. 232:107993. doi: 10.1016/j.pharmthera.2021.107993, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2021.107993</ArticleId><ArticleId IdType="pmc">PMC8930430</ArticleId><ArticleId IdType="pubmed">34587477</ArticleId></ArticleIdList></Reference><Reference><Citation>Garantziotis S., Brezina M., Castelnuovo P., Drago L. (2016). The role of hyaluronan in the pathobiology and treatment of respiratory disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 310, L785&#x2013;L795. doi: 10.1152/ajplung.00168.2015, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00168.2015</ArticleId><ArticleId IdType="pmc">PMC4867348</ArticleId><ArticleId IdType="pubmed">26747781</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellman U., Karlsson M. G., Engstr&#xf6;m-Laurent A., Cajander S., Dorofte L., Ahlm C., et al. . (2020). Presence of hyaluronan in lung alveoli in severe Covid-19: an opening for new treatment options? J. Biol. Chem. 295, 15418&#x2013;15422. doi: 10.1074/jbc.AC120.015967, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.AC120.015967</ArticleId><ArticleId IdType="pmc">PMC7650240</ArticleId><ArticleId IdType="pubmed">32978255</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston C., Hughes H., Lingard S., Hailey S., Healy B. (2022). Immunity and infectivity in covid-19. BMJ 378:e061402. doi: 10.1136/bmj-2020-061402</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2020-061402</ArticleId><ArticleId IdType="pubmed">35777812</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeling M. J. (2023). Patterns of reported infection and reinfection of SARS-CoV-2 in England. J. Theor. Biol. 556:111299. doi: 10.1016/j.jtbi.2022.111299, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtbi.2022.111299</ArticleId><ArticleId IdType="pmc">PMC9568275</ArticleId><ArticleId IdType="pubmed">36252843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y. I., Kim S. M., Park S. J., Kim E. H., Yu K. M., Chang J. H., et al. . (2021). Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission. Emerg. Microbes Infect. 10, 152&#x2013;160. doi: 10.1080/22221751.2021.1872352, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1872352</ArticleId><ArticleId IdType="pmc">PMC7832474</ArticleId><ArticleId IdType="pubmed">33407005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissler S. M., Hay J. A., Fauver J. R., Mack C., Tai C. G., Anderson D. J., et al. . (2023). Viral kinetics of sequential SARS-CoV-2 infections. Nat. Commun. 14:6206. doi: 10.1038/s41467-023-41941-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41941-z</ArticleId><ArticleId IdType="pmc">PMC10556125</ArticleId><ArticleId IdType="pubmed">37798265</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratochvil M. J., Kaber G., Cai P. C., Burgener E. B., Barlow G. L., Nicolls M. R., et al. . Biochemical and Biophysical Characterization of Respiratory Secretions in Severe SARS-CoV-2 (COVID-19) Infections, Infectious Diseases (except HIV/AIDS), medRxiv [Epub ahead of preprint] (2020). doi: 10.1101/2020.09.11.20191692</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.11.20191692</ArticleId><ArticleId IdType="pmc">PMC9309048</ArticleId><ArticleId IdType="pubmed">35730564</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Yang S., Xu P., Zhang D., Tong Y., Chen L., et al. . (2022). SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network. EBioMedicine 76:103861. doi: 10.1016/j.ebiom.2022.103861, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103861</ArticleId><ArticleId IdType="pmc">PMC8811534</ArticleId><ArticleId IdType="pubmed">35124429</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligi D., Della Franca C., Notarte K. I., Goldrich N., Kavteladze D., Henry B. M., et al. . (2023). Platelet distribution width (PDW) as a significant correlate of COVID-19 infection severity and mortality. Clin. Chem. Lab. Med. 62, 385&#x2013;395. doi: 10.1515/cclm-2023-0625, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2023-0625</ArticleId><ArticleId IdType="pubmed">37725416</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov P. V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N. I., et al. . (2023). The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361&#x2013;379. doi: 10.1038/s41579-023-00878-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman M. G., Cohen L. B., Nanau R. M. (2016). Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin. Biochem. 49, 302&#x2013;315. doi: 10.1016/j.clinbiochem.2015.07.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2015.07.019</ArticleId><ArticleId IdType="pubmed">26188920</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen N. N., Nguyen Y. N., Hoang V. T., Million M., Gautret P. (2023). SARS-CoV-2 reinfection and severity of the disease: a systematic review and Meta-analysis. Viruses 15:967. doi: 10.3390/v15040967, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15040967</ArticleId><ArticleId IdType="pmc">PMC10145185</ArticleId><ArticleId IdType="pubmed">37112949</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstr&#xf6;m P., Ballin M., Nordstr&#xf6;m A. (2022). Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect. Dis. 22, 781&#x2013;790. doi: 10.1016/S1473-3099(22)00143-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00143-8</ArticleId><ArticleId IdType="pmc">PMC8971363</ArticleId><ArticleId IdType="pubmed">35366962</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandher R., Bilszta J. L. C. (2023). Novel COVID-19 vaccine hesitancy and acceptance, and associated factors, amongst medical students: a scoping review. Med. Educ. Online 28:2175620. doi: 10.1080/10872981.2023.2175620</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10872981.2023.2175620</ArticleId><ArticleId IdType="pmc">PMC9930839</ArticleId><ArticleId IdType="pubmed">36788502</ArticleId></ArticleIdList></Reference><Reference><Citation>Papakonstantinou E., Bonovolias I., Roth M., Tamm M., Schumann D., Baty F., et al. . (2019). Serum levels of hyaluronic acid are associated with COPD severity and predict survival. Eur. Respir. J. 53:1801183. doi: 10.1183/13993003.01183-2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01183-2018</ArticleId><ArticleId IdType="pubmed">30705130</ArticleId></ArticleIdList></Reference><Reference><Citation>Papanastasopoulou C., Papastamataki M., Karampatsis P., Anagnostopoulou E., Papassotiriou I., Sitaras N. (2017). Cardiovascular risk and serum hyaluronic acid: a preliminary study in a healthy population of low/intermediate risk. J. Clin. Lab. Anal. 31:e22010. doi: 10.1002/jcla.22010, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.22010</ArticleId><ArticleId IdType="pmc">PMC6816791</ArticleId><ArticleId IdType="pubmed">27306798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponti G., Maccaferri M., Ruini C., Tomasi A., Ozben T. (2020). Biomarkers associated with COVID-19 disease progression. Crit. Rev. Clin. Lab. Sci. 57, 389&#x2013;399. doi: 10.1080/10408363.2020.1770685</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408363.2020.1770685</ArticleId><ArticleId IdType="pmc">PMC7284147</ArticleId><ArticleId IdType="pubmed">32503382</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmati M., Udeh R., Yon D. K., Lee S. W., Dolja-Gore X., McEVoy M., et al. . (2023). A systematic review and meta-analysis of long-term sequelae of COVID-19 2-year after SARS-CoV-2 infection: a call to action for neurological, physical, and psychological sciences. J. Med. Virol. 95:e28852. doi: 10.1002/jmv.28852, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28852</ArticleId><ArticleId IdType="pubmed">37288652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauer A., Seeliger B., Jandl K., Erfinanda L., Wilhelm J., Alexopoulos I., et al. . (2022). Circulating hyaluronic acid signature in CAP and ARDS - the role of pneumolysin in hyaluronic acid shedding. Matrix Biol. 114, 67&#x2013;83. doi: 10.1016/j.matbio.2022.11.003, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2022.11.003</ArticleId><ArticleId IdType="pubmed">36456058</ArticleId></ArticleIdList></Reference><Reference><Citation>Semiz S. (2022). COVID19 biomarkers: what did we learn from systematic reviews? Front. Cell. Infect. Microbiol. 12:1038908. doi: 10.3389/fcimb.2022.1038908, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.1038908</ArticleId><ArticleId IdType="pmc">PMC9792992</ArticleId><ArticleId IdType="pubmed">36583110</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Wang Y., Shao C., Huang J., Gan J., Huang X., et al. . (2020). COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 27, 1451&#x2013;1454. doi: 10.1038/s41418-020-0530-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-0530-3</ArticleId><ArticleId IdType="pmc">PMC7091918</ArticleId><ArticleId IdType="pubmed">32205856</ArticleId></ArticleIdList></Reference><Reference><Citation>Solera J. T., &#xc1;rbol B. G., Mittal A., Hall V. G., Marinelli T., Bahinskaya I., et al. . (2024). COVID-19 reinfection has better outcomes than the first infection in solid organ transplant recipients. Transplantation 108, 1249&#x2013;1256. doi: 10.1097/TP.0000000000004902, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004902</ArticleId><ArticleId IdType="pubmed">38291585</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J. B., Murthy S., Marshall J. C., Relan P., Diaz J. V. (2022). A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 22, e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Srikanth S., Boulos J. R., Dover T., Boccuto L., Dean D. (2023). Identification and diagnosis of long COVID-19: a scoping review. Prog. Biophys. Mol. Biol. 182, 1&#x2013;7. doi: 10.1016/j.pbiomolbio.2023.04.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbiomolbio.2023.04.008</ArticleId><ArticleId IdType="pmc">PMC10176974</ArticleId><ArticleId IdType="pubmed">37182545</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T., Jolley S. E., Karlson E. W., Levitan E. B., Levy B., McComsey G. A., et al. . (2023). Development of a definition of Postacute sequelae of SARS-CoV-2 infection. JAMA 329, 1934&#x2013;1946. doi: 10.1001/jama.2023.8823, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuzuki S., Miyazato Y., Terada M., Morioka S., Ohmagari N., Beutels P. (2022). Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients. Health Qual. Life Outcomes 20:125. doi: 10.1186/s12955-022-02033-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-022-02033-6</ArticleId><ArticleId IdType="pmc">PMC9388960</ArticleId><ArticleId IdType="pubmed">35986269</ArticleId></ArticleIdList></Reference><Reference><Citation>Willyard C. (2023). Are repeat COVID infections dangerous? What the science says. Nature 616, 650&#x2013;652. doi: 10.1038/d41586-023-01371-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-01371-9</ArticleId><ArticleId IdType="pubmed">37100944</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu K., Chen Y., Yuan J., Yi P., Ding C., Wu W., et al. . (2020). Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19). Clin. Infect. Dis. 71, 799&#x2013;806. doi: 10.1093/cid/ciaa351, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa351</ArticleId><ArticleId IdType="pmc">PMC7184421</ArticleId><ArticleId IdType="pubmed">32271376</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Ling Y., Zhao F., Li W., Song Z., Wang L., et al. . (2022). Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. Signal Transduct. Target. Ther. 7:91. doi: 10.1038/s41392-022-00952-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00952-w</ArticleId><ArticleId IdType="pmc">PMC8931182</ArticleId><ArticleId IdType="pubmed">35304437</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S. J. (2021). Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect. Dis. 53, 737&#x2013;754. doi: 10.1080/23744235.2021.1924397, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S. J., Halim A., Halim M., Liu S., Aljeldah M., Al Shammari B. R., et al. . (2023). Inflammatory and vascular biomarkers in post-COVID-19 syndrome: a systematic review and meta-analysis of over 20 biomarkers. Rev. Med. Virol. 33:e2424. doi: 10.1002/rmv.2424, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2424</ArticleId><ArticleId IdType="pubmed">36708022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>